School of Medicine

Wayne State University School of Medicine

OPERA: A Study Comparing The Treatment of Ocrelizumab to Rebif® In Patient With Relapsing MS - Closed To Enrollment

This is a 2 year study evaluating the safety and effectiveness of Ocrelizumab versus Rebif in patients with Relapsing MS. Patients will be randomly assigned to receive either Ocrelizumab (IV infusions) every 6 months or 3 times a week Rebif® injections.

 

Eligibility: Patients 18-55 years old with Relapsing MS (Relapsing Remitting or Secondary Progressive MS) and able to walk at least 100 meters without aid or rest.

 

For more information visit: OPERA